Nikolaos Kakouros, PhD
Interventional Cardiology · Worcester, MANPI 1134448012
Payments from drug & device makers
Across 386 payments — averaging $2245.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$479K
- Boston Scientific$199K
- Daiichi Sankyo Inc.$87K
- Abbott$52K
- Edwards Lifesciences$25K
- Magenta Medical Inc$17K
- plus $7K from 4 others
What the payments were for
- Consulting fees$10,16524%
- Speaking & faculty fees$15,87637%
- Travel & lodging$10,94926%
- Food & beverage$5,68813%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 60 | $479,470 |
| Boston Scientific | 61 | $199,355 |
| Daiichi Sankyo Inc. | 113 | $87,102 |
| Abbott | 31 | $51,778 |
| Edwards Lifesciences | 110 | $25,262 |
| Magenta Medical Inc | 1 | $16,851 |
| Philips North America LLC | 4 | $6,395 |
| Ancora Heart, Inc. | 3 | $298 |
| Medtronic | 1 | $135 |
| Abiomed | 2 | $92 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$866,738 in reported general payments places this provider in the 90th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $38,096 |
| BrilintaTicagrelor | 25 | $13,503 |
| Atorvastatin Calcium | 97 | $1,685 |
| Ezetimibe | 23 | $884 |
| Rosuvastatin Calcium | 32 | $856 |
| Amlodipine Besylate | 53 | $602 |
| Metoprolol Succinate | 24 | $582 |
| Losartan Potassium | 25 | $447 |
| Lisinopril | 42 | $355 |
| Furosemide | 61 | $277 |
| Carvedilol | 18 | $200 |
| Metoprolol Tartrate | 29 | $192 |
| Spironolactone | 20 | $150 |
| Amoxicillin | 14 | $16 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Worcester
- Vaikom MahadevanWorcester$724K
- Alvaro Alonso AparicioWorcester$31K
- Jeffrey RadeWorcester$28K
- Waqas QureshiWorcester$19K
- Krishna Sagar GajulaWorcester$14K
- Hafiz GhafoorWorcester$13K
- Charles GibsonBoston$16.3M
- Eric SecemskyBoston$7.3M
- Duane PintoBoston$4.2M
- Suzanne BaronBoston$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.